Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Ocular Therapeutics Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the prepared remarks, we'll conduct a question-and-answer session. To ask a question, please press star 1. As a reminder, this conference call is being recorded and will be available for replay on the Investor Relations section of the Ocular Therapeutics website. I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery, Jr. Please go ahead, Mr. Slattery. Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release and filed our annual report on Form 10-K, outlining our financial results and business updates for the fourth quarter and full year of 2024, along with several updates to our registrational program for Xpaxly and WET-AMD. Ocular's Executive Chairman, President, and CEO, Dr. Praveen Dougal, We'll summarize recent business highlights before we move to our question and answer session. Joining Dr. Dougal for the Q&A portion of the call will be Donald Notman, Chief Financial Officer and Chief Operating Officer, Sanjay Nayak, Chief Strategy Officer, and Steve Myers, Chief Commercial Officer. We refer everyone to this morning's press release and our Form 10-K for a comprehensive update of fourth quarter and full year 2024 financial and business results. During today's call, certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially as a result of a variety of factors including risks and uncertainties identified in the risk factors section of our annual report on Form 10-K ...